368 related articles for article (PubMed ID: 22290264)
1. Studying a complex tumor: potential and pitfalls.
Zheng S; Chheda MG; Verhaak RG
Cancer J; 2012; 18(1):107-14. PubMed ID: 22290264
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.
Heiland DH; Haaker G; Delev D; Mercas B; Masalha W; Heynckes S; Gäbelein A; Pfeifer D; Carro MS; Weyerbrock A; Prinz M; Schnell O
Oncotarget; 2017 Jun; 8(26):42214-42225. PubMed ID: 28178682
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.
Shea A; Harish V; Afzal Z; Chijioke J; Kedir H; Dusmatova S; Roy A; Ramalinga M; Harris B; Blancato J; Verma M; Kumar D
Cancer Med; 2016 Aug; 5(8):1917-46. PubMed ID: 27282910
[TBL] [Abstract][Full Text] [Related]
4. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG
Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244
[TBL] [Abstract][Full Text] [Related]
5. Viral vector: potential therapeutic for glioblastoma multiforme.
Manikandan C; Kaushik A; Sen D
Cancer Gene Ther; 2020 May; 27(5):270-279. PubMed ID: 31316136
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
[TBL] [Abstract][Full Text] [Related]
7. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Verhaak RG; Hoadley KA; Purdom E; Wang V; Qi Y; Wilkerson MD; Miller CR; Ding L; Golub T; Mesirov JP; Alexe G; Lawrence M; O'Kelly M; Tamayo P; Weir BA; Gabriel S; Winckler W; Gupta S; Jakkula L; Feiler HS; Hodgson JG; James CD; Sarkaria JN; Brennan C; Kahn A; Spellman PT; Wilson RK; Speed TP; Gray JW; Meyerson M; Getz G; Perou CM; Hayes DN;
Cancer Cell; 2010 Jan; 17(1):98-110. PubMed ID: 20129251
[TBL] [Abstract][Full Text] [Related]
8. Classification of glioblastoma multiforme in adults by molecular genetics.
Benjamin R; Capparella J; Brown A
Cancer J; 2003; 9(2):82-90. PubMed ID: 12784873
[TBL] [Abstract][Full Text] [Related]
9. Molecular and Genomic Alterations in Glioblastoma Multiforme.
Crespo I; Vital AL; Gonzalez-Tablas M; Patino Mdel C; Otero A; Lopes MC; de Oliveira C; Domingues P; Orfao A; Tabernero MD
Am J Pathol; 2015 Jul; 185(7):1820-33. PubMed ID: 25976245
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma: molecular analysis and clinical implications.
Huse JT; Holland E; DeAngelis LM
Annu Rev Med; 2013; 64():59-70. PubMed ID: 23043492
[TBL] [Abstract][Full Text] [Related]
11. Genomics illuminates a deadly brain cancer.
Kuehn BM
JAMA; 2010 Mar; 303(10):925-7. PubMed ID: 20215599
[No Abstract] [Full Text] [Related]
12. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.
Shen Y; Grisdale CJ; Islam SA; Bose P; Lever J; Zhao EY; Grinshtein N; Ma Y; Mungall AJ; Moore RA; Lun X; Senger DL; Robbins SM; Wang AY; MacIsaac JL; Kobor MS; Luchman HA; Weiss S; Chan JA; Blough MD; Kaplan DR; Cairncross JG; Marra MA; Jones SJM
Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19098-19108. PubMed ID: 31471491
[TBL] [Abstract][Full Text] [Related]
13. Comparison of glioblastoma (GBM) molecular classification methods.
Lee E; Yong RL; Paddison P; Zhu J
Semin Cancer Biol; 2018 Dec; 53():201-211. PubMed ID: 30031763
[TBL] [Abstract][Full Text] [Related]
14. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies.
Jarboe JS; Johnson KR; Choi Y; Lonser RR; Park JK
Cancer Res; 2007 Sep; 67(17):7983-6. PubMed ID: 17804706
[TBL] [Abstract][Full Text] [Related]
15. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.
Gromeier M; Brown MC; Zhang G; Lin X; Chen Y; Wei Z; Beaubier N; Yan H; He Y; Desjardins A; Herndon JE; Varn FS; Verhaak RG; Zhao J; Bolognesi DP; Friedman AH; Friedman HS; McSherry F; Muscat AM; Lipp ES; Nair SK; Khasraw M; Peters KB; Randazzo D; Sampson JH; McLendon RE; Bigner DD; Ashley DM
Nat Commun; 2021 Jan; 12(1):352. PubMed ID: 33441554
[TBL] [Abstract][Full Text] [Related]
16. Emerging insights into the molecular and cellular basis of glioblastoma.
Dunn GP; Rinne ML; Wykosky J; Genovese G; Quayle SN; Dunn IF; Agarwalla PK; Chheda MG; Campos B; Wang A; Brennan C; Ligon KL; Furnari F; Cavenee WK; Depinho RA; Chin L; Hahn WC
Genes Dev; 2012 Apr; 26(8):756-84. PubMed ID: 22508724
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
[TBL] [Abstract][Full Text] [Related]
18. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
19. MRI characteristics and histological changes in glioblastoma after gene therapy.
Weber FW; Floeth FW; Reifenberger G; Felsberg J; Aulich A; Kiwit JC; Bock WJ
Front Radiat Ther Oncol; 1999; 33():244-52. PubMed ID: 10549494
[No Abstract] [Full Text] [Related]
20. Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.
Tabone T; Abuhusain HJ; Nowak AK; ; Erber WN; McDonald KL
J Clin Pathol; 2014 Jul; 67(7):550-5. PubMed ID: 24695838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
